

For Immediate Release

## **Successful Completion of The Trendlines Group Ltd.'s IPO with Strong Investor Interest, S\$25.0 Million Total Proceeds Raised**

- **Placement of 75,760,000 shares priced at S\$0.33 per share; raising gross proceeds of approximately S\$25.0 million**
- **S\$13.7 million investment raised in the pre-IPO stage brings total capital raising amount to approximately S\$38.7 million**
- **B. BRAUN Melsungen AG, a global healthcare supplier, subscribed for S\$7.1 million worth of shares during the placement**
- **Debut trading on Catalist at 9.00 a.m. on 26 November 2015**

**Singapore, 24 November 2015** – The Trendlines Group Ltd. (“**Trendlines**”), an Israeli company focused on developing technology-based companies in the medical and agricultural fields, is pleased to announce today that further to the launch of its initial public offering (“**IPO**”) on the Catalist of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) on 16 November 2015, the placement of its 75,760,000 shares (“**Placement Shares**”) (the “**Placement**”) has been successfully completed.

Trendlines received strong interest from investors and as at the close of the Placement at 12.00 noon on 24 November 2015, all the Placement Shares have been validly subscribed for

and application monies received for these Placement Shares amounted to a total of S\$25,000,800, including S\$7,100,000 from the Company's cornerstone investor, B. BRAUN Melsungen AG ("**B. BRAUN**"), a healthcare supplier with global sales of €5.43 billion.

In addition, Trendlines had raised S\$13.7 million from the Pre-IPO Investors, bringing total IPO-related proceeds to approximately S\$38.7 million.

Commenting on the successful placement of the Placement Shares, Todd Dollinger, Co-Chairman and Co-CEO of Trendlines, said, *"It was encouraging to see such interest from investors. While Trendlines' business model is unusual as compared to most of the listed companies in Singapore, we believe investors understood Trendlines' ability to incubate technology-based companies in the medical and agricultural fields, bring them to commercialisation, and achieve significant returns for investors. The value of investing in Trendlines is well validated by the strategic investment from the Company's cornerstone investor, B. BRAUN."*

Steve Rhodes, Co-Chairman and Co-CEO of Trendlines, added, *"We believe that this successful Placement establishes a great start for Trendlines' trading on the Catalist of SGX-ST. The proceeds raised will place Trendlines in a strong financial position, providing the flexibility to make follow-on investments in portfolio companies, expand into new markets, expand Trendlines Labs, and support and increase the number of portfolio companies. With our plan to establish our first incubator in Singapore in 2016, we look forward to bringing Trendlines' business to the next level and creating value for our shareholders in the long term."*

The listing and trading of Trendlines' shares on Catalist of the SGX-ST is expected to commence on a "ready" basis at 9.00 a.m. on 26 November 2015. PrimePartners Corporate Finance Pte. Ltd. is the Sponsor, Issue Manager and Placement Agent for the IPO.

- The End -

---

#### **About The Trendlines Group Ltd.**

The Trendlines Group Ltd. (the "**Company**") and together with its subsidiaries (the "**Group**"), focuses on developing technology-based companies in the medical and agricultural fields. The Group creates and develops companies in accordance with its mission to improve the human condition. To this end, the Group discovers, invests in, incubates and provides services to life sciences companies in the fields of medical and agricultural technologies.

The Group operates principally through its two operating subsidiaries, namely, Trendlines Medical – Misgav Ltd. ("**Trendlines Medical**") and Trendlines Agtech – Mofet Ltd. ("**Trendlines Agtech**"), as well

as through its own internal innovation centre, Trendlines Labs. Trendlines Medical focuses on the discovery and development of novel and disruptive medical devices and technologies while Trendlines Agtech focuses on the discovery and development of new agricultural and food technologies. Through Trendlines Labs, the Group engages in research and development activities to create new technologies, either as principal or in collaboration with global and local companies and partners, to address unmet market needs.

---

Issued for and on behalf of The Trendlines Group Ltd.

By Financial PR Pte Ltd.

For more information, please contact:

Romil SINGH / Reyna MEI

romil@financialpr.com.sg / reyna@financialpr.com.sg

Tel: (65) 6438 2990, Fax: (65) 6438 0064

### **IMPORTANT NOTICE**

Capitalised terms used herein shall, unless otherwise defined, bear the same meanings assigned to them in the Offer Document (as defined herein).

This news release is for informational purposes only and does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities of The Trendlines Group Ltd. ("**Company**") nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever. The summary information herein does not purport to be complete and should be read in conjunction with, and is qualified in its entirety by the detailed information in the final offer document of the Company dated 16 November 2015 ("**Offer Document**") that has been registered by the Singapore Exchange Securities Trading Limited ("**SGX-ST**"), acting as agent on behalf of the Monetary Authority of Singapore on 16 November 2015. Information contained in this news release does not constitute part of the Offer Document. This news release does not contain any information that is not included in the Offer Document. Any decision to purchase or subscribe for the shares of the Company ("**Shares**") should be made solely on the basis of information contained in the Offer Document after seeking appropriate professional advice, and no reliance should be placed on any information other than that contained in the Offer Document. The information in this news release should not be relied upon as representation or warranty of the Company.

This news release may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future events, actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors, such as known and unknown risks and uncertainties, and assumptions. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those

expressed or implied by the forward- looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this news release only.

While the Company and PrimePartners Corporate Finance Pte. Ltd. have undertaken reasonable actions to ensure that the information extracted from the report by Ernst & Young (Israel) Ltd. titled "Israel's High-Tech Industry Overview – Final Report – October 2015" dated 20 October 2015 as set out in Appendix G of the Offer Document is reproduced in its proper form and context, and that the information is extracted accurately and fairly from such report, neither the Company nor PrimePartners Corporate Finance Pte. Ltd. has conducted an independent review of the information contained in such report nor verified the accuracy of the contents of the relevant information.

None of the Company, PrimePartners Corporate Finance Pte. Ltd. or any of their respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this news release or its contents or otherwise arising in connection with this news release, to the extent permitted by law.

Neither this news release nor any of its content may be used without the prior written consent of the Company.

A printed copy of the Offer Document and the application form may be obtained on request, subject to availability, during normal office hours from the office of PrimePartners Corporate Finance Pte. Ltd. at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318. An electronic copy of the Offer Document is also available on the SGX-ST website at <http://www.sgx.com>.